•Controversial registration of aducanumab for Alzheimer's Disease•Aducanumab is the subject of post-licensing observational studies aiming to follow the effects of the drug•Given the high prevalence of cerebrovascular pathology it is important that these studies do not ignore vascular cognitive disorders•The studies may give detailed phenotyping data that may lead to knowledge of targets for treatments of patients with vascular cognitive disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616233 | PMC |
| http://dx.doi.org/10.1016/j.cccb.2022.100044 | DOI Listing |
Publication Analysis
Top Keywords
vascular cognitive
12
aducanumab treatment
4
treatment alzheimer's
4
alzheimer's disease
4
disease vascular
4
cognitive disorders?
4
disorders? •controversial
4
•controversial registration
4
registration aducanumab
4
aducanumab alzheimer's
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!